8,778,360 OCR.pdf (1.71 MB)
Extracellular matrix cancer vaccine adjuvant
standard
posted on 2017-06-22, 00:00 authored by Mark A. Suckow, William R. WolterCompositions suitable for use as adjuvants in the preparation of vaccines, particularly those vaccines useful in the treatment of cancer, are provided. Methods for inhibiting tumor growth in an animal are also disclosed. Methods for immunizing an animal against cancer, such as prostate cancer, are also described. The adjuvants described are comprised of an extracellular matrix material, such as small intestinal submucosal (SIS) tissue. The preparations may take the form of sheets, gels, liquids (injectable), trocar, or other solid or semi-solid preparation. The invention provides for enhanced tumor inhibition of 2-fold or greater, compared to vaccine preparations without the extracellular matrix material, or from 4- to 5-fold, compared to preparations without the adjuvant promoting extracellular materials.
History
Patent Number
US 8,778,360 B2Other Application
11/583,771Inventor
Mark A. Suckow William R. WolterInventor from Local Institution
Mark A. Suckow William R. WolterAssignee
University of Notre Dame du LacDate Modified
2017-06-22Language
- English
Claims
19Prior Publication Number
US 20100233214 A1Publisher
U.S. Patent and Trademark OfficeCooperative Patent Classification Codes
A61K 39/0011 (20130101); A61K 2039/5152 (20130101); A61K 2039/55511 (20130101)Contributor
Mark A. Suckow|William R. WolterInternational Patent Classification Codes
A61K 9/00 (20060101); A61K 9/14 (20060101); A61K 9/70 (20060101)US Patent Classification Codes
424/277.1; 424/423; 424/443; 424/484; 424/489Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC